文献速递中医内科针灸推拿中药与中成药合理使用

中国掌部多汗症门诊患者治疗现状调查:药物治疗不足与需求未满足间的显著差距

A significant gap between inadequate pharmacotherapy and substantial unmet needs in palmar hyperhidrosis management in China: insights from a questionnaire-based survey among outpatients.
PubMed 文献 · Front Pharmacol · 2026-01-08

一项在中国三级胸外科门诊连续患者中开展的匿名问卷调查研究,共收集363份有效问卷,评估掌部多汗症的治疗模式与药物治疗充分性。结果显示,87.3%的患者为重度(HDSS 3-4级),仅38.1%曾接受药物治疗,32.6%曾使用中医疗法,现有药物疗效有限且不良反应常见,但50.0%患者仍愿意未来接受药物治疗,偏好局部制剂和减少给药频率。

要点

  • 掌部多汗症患者以重度为主,药物治疗使用率低,中医疗法使用较普遍但疗效有限。
  • 既往药物治疗主要顾虑为疗效不足和局部皮肤刺激,但未显著降低未来用药意愿。
  • 性别和疾病严重程度是治疗选择的重要决定因素,半数患者仍愿意尝试未来药物治疗,偏好局部制剂和低频给药。

核心结论

  • 中国掌部多汗症管理不充分且治疗结果欠佳,现有药物治疗选择受限于可及性低、疗效不足和获批药物范围窄,与患者巨大需求之间存在显著脱节。

主要发现

  • 87.3%的患者为HDSS 3-4级重度疾病,97.8%表现为掌部多汗症。
  • 仅38.1%曾接受药物治疗,32.6%曾使用中医疗法(包括中药、针灸、推拿等)。
  • 既往最常用的药物治疗为止汗剂(28.6%)和中药(25.0%),但两者疗效均有限。
  • 52.9%的患者在门诊就诊前对手术干预有一般了解;50.0%的患者仍愿意未来接受药物治疗,偏好局部制剂(29.3%)和减少给药频率(31.6%)。
  • 性别和疾病严重程度是治疗选择的显著决定因素;既往无效或副作用等负面体验未显著降低未来药物治疗意愿。

关键数值与推荐

  • 87.3%的患者HDSS分级为3-4级(重度)。
  • 38.1%有既往药物治疗史,32.6%曾使用中医疗法。
  • 止汗剂使用率28.6%,中药使用率25.0%。
  • 50.0%愿意未来接受药物治疗,其中29.3%偏好局部制剂,31.6%偏好减少给药频率。

临床怎么用

  • 对掌部多汗症患者应评估既往药物治疗史及中医疗法使用情况,关注疗效不足和皮肤刺激等常见问题。
  • 尽管既往治疗体验不佳,半数患者仍愿意尝试药物治疗,可针对偏好局部制剂和低频给药的患者个体化选择方案。
  • 性别和疾病严重程度可影响治疗选择,临床决策时应予以考虑。

局限性

  • 本研究为单中心问卷调查研究,样本来自三级胸外科门诊,可能存在选择偏倚。
  • 研究未报告问卷的具体内容、信效度验证及应答率等细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Palmar hyperhidrosis, characterized by excessive sweating primarily affecting the hands, significantly impairs quality of life and psychological well-being. Although topical agents, iontophoresis, microwave therapy, and sympathectomy are established interventions, real-world treatment patterns and pharmacotherapeutic adequacy among Chinese patients remain poorly delineated. METHODS: An anonymous, questionnaire-based survey was conducted among consecutive patients at a tertiary thoracic surgery clinic in China between March 2023 and October 2024. A total of 363 valid responses were collected and analyzed using SPSS 27.0. Descriptive statistics and multivariable logistic regression were used to evaluate treatment patterns, patient preference, and predictors of treatment selection. RESULTS: The study cohort was composed predominantly of individuals with severe disease (87.3% HDSS grade 3-4), and nearly all participants (97.8%) presented with palmar hyperhidrosis. Regarding treatment history, only 38.1% had previously received pharmacotherapy, while 32.6% had utilized Traditional Chinese Medicine (TCM) therapeutic approaches, including TCM, acupuncture, massage and manipulation therapies. Antiperspirants (28.6%) and TCM (25.0%) were the most frequently used prior pharmacotherapies, yet both were associated with limited therapeutic efficacy. According to our survey, owing to high symptom severity, 52.9% had a general knowledge of surgical intervention before the outpatient visit. Primary concerns regarding previous pharmacotherapy included insufficient efficacy and localized adverse effects, particularly skin irritation. Notably, 50.0% of participants remained receptive to future pharmacotherapy, showing a preference for topical formulations (29.3%) and reduced dosing frequency (31.6%). Gender and disease severity were identified as significant determinants of treatment choice. Importantly, prior negative experiences - such as inefficacy and side effects - did not significantly diminish willingness to consider future pharmacologic treatment. CONCLUSION: Inadequate management and suboptimal treatment outcomes represent considerable challenges in the care of palmar hyperhidrosis in China. Existing pharmacotherapeutic options are constrained by limited availability, inadequate efficacy, and a narrow range of approved agents - a reality that highlights a critical disconnect with substantial patient demand. These findings underscore an urgent need to accelerate drug development and clinical translation in this field.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Pang N, Liu Y, Ma C, et al. A significant gap between inadequate pharmacotherapy and substantial unmet needs in palmar hyperhidrosis management in China: insights from a questionnaire-based survey among outpatients. Front Pharmacol. 2026. PMID: 41585901. doi:10.3389/fphar.2025.1715189

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。